Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker

基于非侵入性棒状能量景观生物标志物减轻色素性视网膜炎

• 批准号: 10733154
• 负责人: BRUCE A. BERKOWITZ
• 金额: $ 50.18万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10733154
• 关键词: Acceleration; Address; Atrophic; Biological Assay; Biological Markers; Blindness; Cell Culture Techniques; Cessation of life; Clinic; Clinical Treatment; Cone; Darkness; Diet; Disease; Early Diagnosis; Ecosystem; Electron Microscopy; Etiology; Evolution; Experimental Models; Exposure to; Friends; Functional disorder; Future; Genes; Genetic; Histologic; Hour; Inherited; Knowledge; Light; Measurement; Measures; Methylene blue; Mitochondria; Mouse Strains; Mus; Mutation; Names; Natural History; Nuclear Hormone Receptors; Onset of illness; Optical Coherence Tomography; Oxygen Consumption; Pathogenicity; Pathology; Patient-Focused Outcomes; Patients; Performance; Periodicity; Prediction of Response to Therapy; Public Health; Receptor Gene; Reporting; Research; Retinitis Pigmentosa; Rod; Shapes; Signal Transduction; Synthetic Progestogens; Technology; Testing; Time; Tissues; Transducin; Treatment Efficacy; Treatment outcome; Up-Regulation; Vertebrate Photoreceptors; Vision; Wild Type Mouse; alpha Subunit Transducin; bench to bedside; biomarker performance; clinically relevant; dark rearing; experimental study; human model; imaging biomarker; imaging modality; improved; improved outcome; indexing; innovation; loss of function mutation; mitochondrial dysfunction; neuroprotection; non-invasive imaging; novel; personalized management; phosphodiesterase 6; phosphoric diester hydrolase; photoreceptor degeneration; postnatal; prevent; restoration; retinal rods; translational barrier

Project Summary / Abstract: Retinitis pigmentosa (RP) is a disease that leads to untreatable and irreversible cone death and blindness. A myriad of loss-of-function mutations, including in transducin 1 or phosphodiesterase 6 genes, underlie RP. Ex vivo studies from experimental models support abnormal mitochondria performance as a common pathogenic condition leading to RP pathology. However, evaluating such mitochondrial abnormalities in patients is not possible and a one-therapy-fits-all approach is unlikely to improve outcomes patient diversity. Addressing these major knowledge gaps will require a patient-friendly, non-invasive biomarker of mitochondria performance. Recently, we discovered a novel index of mitochondria performance based on a feature that is readily identifiable in optical coherence tomography (OCT), the inner segment ellipsoid zone (ISez). Our first-in-kind studies in wild-type mice show that the shape of the ISez profile changes from elongated during a low energy demand condition (light) to rounder during a high energy demand condition (dark). The underlying mitochondria etiology of the change in ISez profile shape is supported by electron microscopy and oxygen consumption rate measurements in two mice strains with distinct mitochondria activity. For example, OCT examination of cyclic-light reared 2-month-old mice with a mutation in the α subunit of transducin 1 (Gnat1rd17) shows modest rod loss with a rounder-than-normal ISez and higher rate of oxygen consumption than in the dark, biomarker evidence for early mitochondria overperformance. Also, at postnatal (P) day 23, dark-reared mice with a mutation in the rod phosphodiesterase 6b gene (Pde6brd10) show modest rod loss together with rounder-than-normal ISez when examined in the dark, biomarker evidence for mitochondria overperformance. When P23 dark-reared Pde6brd10 mice are exposed to room light for 1 hour they showed a more-elliptical-than-normal ISez shape suggesting rod mitochondria underperformance. This is notable because, whilst the 1 hour of light did not cause immediate additional rod death, accelerated rod loss reportedly occurs days later after continued dark- rearing. These considerations show that the ISez profile shape is sensitive to abnormalities in the rod energy landscape that precede later rod loss. The natural history of change of the ISez profile shape as it relates to rod atrophy in cyclic-light reared Gnat1rd17 or Pde6brd10 mice is unknown. Our working hypothesis is that restoring our mitochondria performance biomarker (the ISez profile shape) to wild-type-like levels predicts pro-survival treatment outcomes in experimental IRD. These studies introduce an innovative and clinically relevant imaging biomarker, the ISez profile shape, for assessing treatment efficacy in RP/IRD. Therapies that restore the ISez profile shape to normal are ultimately expected to prevent loss of sight in patients with IRD.

项目摘要/摘要：色素性视网膜炎（RP）是一种治疗不治之症